FDA approves Gilead's Genvoya for HIV

FDA approved Genvoya tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine from Gilead Sciences Inc. (NASDAQ:GILD) to treat HIV-1 infection in patients ages 12 and older.

Gilead plans to launch the drug next week at an annual wholesale acquisition cost (WAC) of $31,362. ...